Evidence map›Paper›PMID 39832869›Full record

ReviewAnalytica chimica acta2025

Emerging opportunities for intact and native protein analysis using chemical proteomics.

Alexis N Edwards, Ku-Lung Hsu

Abstract readReview
In one paragraph

Review in Analytica chimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Methods for the Investigation of Protein-Ligands Interactions.Advances in experimental medicine and biology · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alexis N EdwardsDepartment of Chemistry, University of Texas at Austin, Austin, TX, 78712, United States.
Ku-Lung HsuDepartment of Chemistry, University of Texas at Austin, Austin, TX, 78712, United States. Electronic address: ken.hsu@austin.utexas.edu.

Funding

Endocannabinoid Biosynthesis in Inflammation and PainR01DA043571 · NIDA · UNIVERSITY OF VIRGINIA · PI Ku-Lung Hsu · 2017 to 2026
$3.5M
Defining and targeting substrate specificity of protein tyrosine phosphatasesR01GM144472 · NIGMS · UNIVERSITY OF VIRGINIA · PI HSU, KU-LUNG · 2022 to 2025
$1.6M
Chemical proteomic investigation of lipid kinase specificity and druggabilityR01AI169412 · NIAID · UNIVERSITY OF VIRGINIA · PI Ku-Lung Hsu · 2023 to 2026
$1.5M
NIAID NIH HHS R01 AI169412NIDA NIH HHS R01 DA043571NIGMS NIH HHS R01 GM144472
6 · The paper itself

Abstract

Chemical proteomics has advanced small molecule ligand discovery by providing insights into protein-ligand binding mechanism and enabling medicinal chemistry optimization of protein selectivity on a global scale. Mass spectrometry is the predominant analytical method for chemoproteomics, and various approaches have been deployed to investigate and target a rapidly growing number of protein classes and biological systems. Two methods, intact mass analysis (IMA) and top-down proteomics (TDMS), have gained interest in recent years due to advancements in high resolution mass spectrometry instrumentation. Both methods apply mass spectrometry analysis at the proteoform level, as opposed to the peptide level of bottom-up proteomics (BUMS), thus addressing some of the challenges of protein inference and incomplete information on modification stoichiometry. This Review covers recent research progress utilizing MS-based proteomics methods, discussing in detail the capabilities and opportunities for improvement of each method. Further, heightened attention is given to IMA and TDMS, highlighting these methods' strengths and considerations when utilized in chemoproteomic studies. Finally, we discuss the capabilities of native mass spectrometry (nMS) and ion mobility mass spectrometry (IM-MS) and how these methods can be used in chemoproteomics research to complement existing approaches to further advance the field of functional proteomics.

Indexed as

ProteinsProteomicsHumansMass SpectrometryProteins

Identifiers

PMID39832869
PMCPMC12684435

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.